BioCardia, Inc.
NCM: BCDALive Quote
About BioCardia, Inc.
Healthcare
Biotechnology
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
📊 Fundamental Analysis
BioCardia, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -950.1%, which indicates that capital utilization is currently under pressure.
At a current price of $1.18, BCDA currently trades near the bottom of its 52-week range (8%), indicating potential value or weakness (Range: $1.00 - $3.20).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$9.78M
Trailing P/E
--
Forward P/E
-2.11
Beta (5Y)
0.55
52W High
$3.20
52W Low
$1.00
Avg Volume
67K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App